OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Thanks to our reviewers 2021!	90
Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?	40
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	38
The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics	36
Authors’ response to letter to editor	35
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	29
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia	28
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	21
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	21
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	18
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	14
Learning pharmacometric covariate model structures with symbolic regression networks	12
Concentration-QTc analysis with two or more correlated baselines	12
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	12
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals	12
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	11
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	10
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	10
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	9
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	9
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	9
Correction: External control arms for rare diseases: building a body of supporting evidence	8
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	8
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	8
Likelihood comparisons in bounded outcome score analysis must be internally consistent	8

Should patients skip late doses of medication? A pharmacokinetic perspective	7
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	7
Visual predictive check of longitudinal models and dropout	7
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	7
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	7
Individualized optimization of colistin loading doses	7
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	7
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	7
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 2. THR-687	7
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	7
Delay differential equations based models in NONMEM	6
Clinical validation of translational antibody PBPK model using tissue distribution data generated with 89Zr-immuno-PET imaging	6
Evaluation of covariate effects using variance-based global sensitivity analysis in pharmacometrics	6
Special issue: chronopharmacometrics	6
Implementation of non-linear mixed effects models defined by fractional differential equations	6
Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable	6
A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory	6
Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials	6
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	5
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	5
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	5
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling	5
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	5
A PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients	5
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	5
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	5
Generation and application of avatars in pharmacometric modelling	5
Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans	5
An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions	4
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	4
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	4
Recommendations for a standardized publication protocol for a QSP model	4
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC	4
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	4
A review of the physiological effects of microgravity and innovative formulation for space travelers	4
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	4
Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-development	4
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	4